Additionally, a study conducted by Kim and colleagues revealed that the JAK1 inhibitor CJ14939 successfully reversed resistance to erlotinib, significantly enhancing the drug's ability to induce cell death in NSCLC cells that had developed resistance.61 This evidence concerns the gene JAK1 and non-small cell lung carcinoma.